These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12469926)

  • 1. Rituxan delays disease progression in indolent non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2002 Nov; 16(11):1472. PubMed ID: 12469926
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
    Akhtar S; Maghfoor I
    J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A
    Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy for low-grade lymphomas: has the time come?
    Cartron G; Solal-Céligny P
    Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
    Maloney DG; Press OW
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
    Traullé C; Coiffier BB
    Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituxan: the new kid on the block.
    Jonas C
    Oncol Nurs Forum; 1998 May; 25(4):669. PubMed ID: 9599347
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to the management of Non-Hodgkin's lymphoma.
    Estes J
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):1-2. PubMed ID: 11878045
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract]   [Full Text] [Related]  

  • 14. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
    Korolenko VO; Gershanovich ML; Tikhonova VV
    Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
    [No Abstract]   [Full Text] [Related]  

  • 15. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
    Williams ME
    Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: moving targets.
    van Oers MH
    Neth J Med; 2009 Sep; 67(8):309-10. PubMed ID: 19767656
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy.
    Tsutsumi Y; Ichiki K; Shiratori S; Kawamura T; Tanaka J; Asaka M; Imamura M; Masauzi N
    Int J Lab Hematol; 2009 Aug; 31(4):468-70. PubMed ID: 18294236
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma.
    Morrison VA
    Oncology (Williston Park); 2007 Aug; 21(9):1104-10. PubMed ID: 17910313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.